Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259467 | 0.78 | ADRB2 (0.54) | ADRB3MEN1KMT2AADRB1ADRB2 | |
| SCHEMBL2197422 | 0.77 | BCHE (0.47) | ADRB3BCHEACHEADRB1ADRB2 | |
| SCHEMBL2199004 | 0.77 | BCHE (0.47) | ADRB3BCHEACHEADRB1ADRB2 | |
| SCHEMBL5064894 | 0.72 | ALDH1A1 (0.52) | MEN1KMT2A | |
| SCHEMBL4271951 | 0.71 | KDM4E (0.63) | BCHE | |
| SCHEMBL5061444 | 0.70 | KMT2A (0.43) | ADRB3MEN1KMT2AADRB1ADRB2 | |
| SCHEMBL20791688 | 0.69 | L3MBTL1 (0.53) | MEN1KMT2A | |
| SCHEMBL20791689 | 0.69 | L3MBTL1 (0.53) | MEN1KMT2A | |
| Alcohol SCHEMBL28032632 | 0.69 | MEN1 (0.64) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8672635 | 0.69 | ADRB3 (0.54) | ADRB3BCHEADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | ADRB3 3338/4885BCHE 3462/4885ACHE 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.